Skip to Content
Merck
All Photos(2)

Key Documents

PCYTMG-40K-PX23

Millipore

MILLIPLEX® Non-Human Primate Cytokine Magnetic Bead Panel - Premixed 23 Plex - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology in non-human primate serum, plasma and cell culture samples.

Synonym(s):

Luminex® non-human primate cytokine immunoassay, Millipore non-human primate cytokine panel, Monkey cytokine multiplex kit

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.47

Quality Level

species reactivity

nonhuman primates

manufacturer/tradename

Milliplex®

assay range

accuracy: 70-101%
linearity: 110.3%
(1:06)

linearity: 121.6%
(1:12)

linearity: 126.2%
(1:24)

standard curve range: 12.2-50,000 pg/mL
(IL-10, IL-18)

standard curve range: 2.4-10,000 pg/mL
standard curve range: 4.9-20,000 pg/mL
(IL-4)

technique(s)

multiplexing: suitable

compatibility

configured for Premixed

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

The immune system is an organized complex network of biological structures and processes that protect against disease. For example, cytokine and chemokines mediate interactions between cells directly, regulating target immune cell responses. These responses result in inflammation where the immune system attempts to eradicate foreign antigens and begin the healing process. Consequently, the inflammatory process plays a key protective role in immunity. In addition, cytokine and chemokine research is essential in understanding the immune system and its multi-faceted response to most antigens, as well as disease states such as autoimmune disease, allergic reactions, sepsis, and cancer.

The MILLIPLEX® Non-Human Primate Cytokine panel is to be used for the simultaneous quantification of any or all of the following in tissue/cell lysate and culture supernatant
samples and serum or plasma samples: G-CSF, GM-CSF, IFNγ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL8, IL-10, IL-12/23(p40), IL-13, IL-15, IL-17A, MCP-1, MIP-1β, MIP-1α, sD40L, TGF-α, TNF-α, VEGF, and IL-18.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Specificity

Cross Reactivty
The antibody pairs in the panel are specific only to the desired analyte and exhibit no or negligible cross-reactivity with other analytes in the panel
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: G-CSF, GM-CSF, IFN-γ, IL-1Ra, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12/23 (p40), IL-13, IL-15, IL-17A, IL-18, MCP-1, MIP-1α, MIP-1β, sCD40L, TGF-α, TNF-α, VEGF-A
  • Recommended Sample type: Serum, plasma, and cell culture supernatants
  • Recommended Sample dilution: Neat
  • Assay Run Time: Overnight or one day. For best results, an overnight incubation is recommended
  • Research Category: Inflammation & Immunology

Packaging

Premixed beads for your convenience.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Sensitivity: Refer to kit protocol for sensitivities for individual cytokines/chemokines
Standard Curve Range: Refer to QC analysis sheet for exact concentration (sCD40L, TNFα)

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

G-CSF, GM-CSF, IFN-γ, IL-1ra, IL-1ß, IL-2, IL-5, IL-6, IL-8, IL-12/23 (p40), IL-13, IL-15, IL-17, MCP-1, MIP-1α, MIP-1ß, TGF-α, VEGF
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wuze Ren et al.
AIDS (London, England), 29(10), F1-F8 (2015-06-04)
Gender differences in immune response and the rate of disease progression in HIV-infected individuals have been reported but the underlying mechanism remains unclear, in part because of the lack of relevant animal models. Here, we report a novel nonhuman primate
Norma Olivares-Zavaleta et al.
Journal of immunology (Baltimore, Md. : 1950), 192(10), 4648-4654 (2014-04-09)
Trachoma, caused by the obligate intracellular organism Chlamydia trachomatis, is the world's leading cause of preventable blindness for which a vaccine is needed. We have previously shown that a plasmid-deficient live-attenuated trachoma vaccine delivered ocularly to macaques elicited either solid
Malika Aid et al.
Cell, 169(4), 610-620 (2017-05-02)
Zika virus (ZIKV) is associated with severe neuropathology in neonates as well as Guillain-Barré syndrome and other neurologic disorders in adults. Prolonged viral shedding has been reported in semen, suggesting the presence of anatomic viral reservoirs. Here we show that
Laura Hocum Stone et al.
Scientific reports, 11(1), 2340-2340 (2021-01-29)
Cytokine profiling is a valuable tool for monitoring immune responses associated with disease and treatment. This study assessed the impact of sex and sedation on serum cytokines in healthy nonhuman primates (NHPs). Twenty-three cytokines were measured from serum using a
Makoto Saito et al.
Nature communications, 12(1), 2654-2654 (2021-05-13)
Most anti-influenza drugs currently used, such as oseltamivir and zanamivir, inhibit the enzymatic activity of neuraminidase. However, neuraminidase inhibitor-resistant viruses have already been identified from various influenza virus isolates. Here, we report the development of a class of macrocyclic peptides

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service